Kanya Rajangam
President, Chief Medical Officer & Head of Research & Development Senti Biosciences Inc.
Dr. Rajangam is responsible for leading the overall research and clinical development of Senti pipeline products. She served in leadership roles at various biotech companies, most recently Nkarta Therapeutics where, as chief medical officer, she was responsible for clinical development of CAR-NK cell therapies for oncology. Prior to Nkarta, she was chief medical officer at Atara Biotherapeutics where she led the development of T-cell therapies for oncology, neurology and infectious diseases. Prior to that, she was chief medical officer of Cleave Biosciences. She contributed to the clinical development and global approval of Kyprolis®, Cotellic® and Cometriq®/Cabometyx®. She received a medical degree from St. Johns’ Medical College and a Ph.D. from Northwestern University.
Seminars
- Exploring predictive patient and donor biomarkers to determine the cell therapy modalities best suited for individual patients and disease contexts
- Identifying pre-infusion and on-treatment biomarker signals to understand response dynamics and guide clinical decision making
- Evaluating immune fitness and safety related biomarkers to identify patients at risk, anticipate challenges, and enhance therapeutic outcomes
- Demonstrating clinical outcomes from phase 1 trials
- Exploring predictive biomarkers to optimize response, safety and trial design in allogeneic therapies
- Showcasing how clinical data enabled regulatory progress and informed pivotal study strategies
